Day: October 21, 2025

79 clinical sites across 23 US states are currently enrolling patients in BriaCell’s pivotal Phase 3 study in metastatic breast cancer (MBC)  Dartmouth Cancer Center, Cedars-Sinai Medical Center, and Winship Cancer Institute of Emory University have now joined BriaCell’s extensive national networkPHILADELPHIA and VANCOUVER, British Columbia, Oct. 21, 2025 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce the addition of several key large cancer centers to its ongoing pivotal Phase 3 clinical study (ClinicalTrials.gov as NCT06072612), notably Dartmouth Cancer Center, Cedars-Sinai Medical Center, and Winship Cancer Institute of Emory University....

Mikra product lineup features new formulations and fresh branding at accessible prices to attract U.S. consumers and drive sustainable growth TORONTO, Oct. 21, 2025 (GLOBE NEWSWIRE) — Lifeist Wellness Inc. (“Lifeist” or the “Company”) (TSX.V: LFST; OTCQB: LFSWF; FRANKFURT: M5B0) announces the return of its Mikra brand to Amazon.com in the United States with a lineup featuring new performance-based products, refreshed formulations and attractive packaging designed to elevate customer engagement. The new Mikra storefront can be found here. “We’re making it easier for U.S. consumers to discover and shop Mikra’s growing portfolio of performance-enhancing products,” said Andrea Judge, CEO of Lifeist. “Our revitalized brand and expanded portfolio of innovative formulations are shaped by consumer insights and market learnings. We’re also...

Vancouver, Canada, Oct. 21, 2025 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the enrollment of the last patient for the first cohort of its Phase I/IIa clinical trial evaluating CMND-100, the Company’s proprietary MEAI-based oral drug candidate for the treatment of Alcohol Use Disorder (AUD). To date, six patients have been successfully enrolled into the trial, Of these, two patients were enrolled at Johns Hopkins University School of Medicine and four at Yale School of Medicine’s Department of Psychiatry. The multinational, multicenter Phase I/IIa trial is designed as a single- and multiple-dose...

JENA, Germany, Oct. 21, 2025 (GLOBE NEWSWIRE) — InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced its participation in the Guggenheim Securities 2nd Annual Healthcare Innovation Conference. Details are as follows: Guggenheim Securities 2nd Annual Healthcare Innovation ConferenceNovember 10 – 12, 2025 in Boston, MAFireside chat on November 11 at 2:30 PM ET InflaRx will also conduct one-on-one investor meetings on November 11th. A link to view the fireside chat live stream and its replay is available here. About InflaRx InflaRx (Nasdaq: IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5a receptor technologies to discover, develop and commercialize highly...

21 October 2025 Middlefield Canadian Income PCC (the “Company”)Including Middlefield Canadian Income – GBP PC (the “Fund”), a cell of the CompanyRegistered No: 93546 Legal Entity Identifier: 2138007ENW3JEJXC8658 Result of Elections In connection with the proposals for the reconstruction and winding up of Middlefield Canadian Income PCC (the “Company”) and Middlefield Canadian Income – GBP PC (the “Fund”) and the option for Fund Shareholders to receive shares in a newly established, actively managed, listed and London Stock Exchange traded fund in the form of an authorised UCITS (the “ETF”) and/or a cash exit at close to the Fund’s net asset value per share, in exchange for their shareholding in the Fund (the “Scheme”), the Board of the Company today announces the result of the Elections made by Fund Shareholders. Elections for the Cash...

Category: Changes board/management/auditors OMA SAVINGS BANK PLC, STOCK EXCHANGE RELEASE 21 OCTOBER 2025 AT 14:15 PM CHANGES IN BOARD/MANAGEMENT/AUDITORS Markus Souru steps down from his role in Oma Savings Bank’s management team Oma Savings Bank’s Head of service network and member of the management team, Markus Souru, will step down from his role on 21 October 2025. Marku Souru will continue working for the company in other duties until 31 December 2025. Area Director Markus Lauri has been appointed as interim Head of service network. “I would like to take this opportunity to thank Markus Souru for his work in developing the bank’s business, and I wish him all the best for the future,” says Karri Alameri, OmaSp CEO. Oma Savings Bank Plc Additional information: Karri Alameri, CEO, tel. +358 45 656 5250, karri.alameri@omasp.fi Distribution: Nasdaq...